Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and tolerability of the combination of
BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.